The 51st Annual Conference of the European Society for Blood and Marrow Transplantation: Physicians – Poster Presentations (P001-P909)

1

Obe-cel demonstrates high efficacy in patients aged ≥55 years with relapsed or refractory B-cell acute lymphoblastic leukemia.
2

The overall remission rate for patients aged ≥55 years treated with obe-cel was 87.5%, with a median follow-up of 20.1 months.
3

Severe adverse events like Grade ≥3 cytokine release syndrome and neurotoxicity were low, occurring in 2.1% and 10.4% of patients, respectively.
4

Treatment-related mortality within three months post-infusion of obe-cel was reported at 4.2% among the study participants.
5

The findings suggest that obe-cel has a favorable benefit/risk profile, making it a viable treatment option for older patients with R/R B-ALL.

Bone Marrow Transplantation

1